How Beauty Can Make Watertight Claims from Lab to Shelf
Kacey Culliney's reporting includes a quoted contribution from Varun on evidence and beauty claims.
The source uses the historical VARUNÉ Labs name.
The published work
Find a question
worth exploring.
Essays, published contributions, interviews and audio featuring Varun Sharma. Browse by subject, source or format.
Each entry identifies where the work appeared and how Varun contributed.
From capacity to capability: Five proofs for India’s pharma future
A contributed argument about the evidence behind pharmaceutical capability and the work that follows an announcement.
AI and Accountability: When Does a Suggestion Become a Decision?
A conversation about judgement, responsibility and the point where a suggestion begins to influence action.
Approval is not access: Pilots’ real test is implementation
Varun examines the work between medicines approval, implementation and access.
Five questions to test whether an AI stack is truly under your control
Five questions about the control an organisation retains over the AI systems it uses.
India’s pharma quality reset will be won after the inspector leaves
A contributed perspective on pharmaceutical quality after the inspection itself has ended.
The publisher may require sign-in.
When three medicines numbers can all be right
Three figures can describe different parts of a medicines question. The article asks which denominator, period and task each one actually supports.
What feasibility support should actually buy
A view of feasibility funding as a way to answer a defined question and decide what work should happen next.
What feasibility research must prove
What makes a feasibility result useful, and which uncertainties should remain visible before a larger commitment.
The 30p rule: how discipline builds trust
A small shop-floor decision opens a larger question about margins, consistency and the promises behind a sale.
From invention to adoption: the work between
The authority, evidence and practical work needed to carry an invention into use.
From hyperfocus to governed execution
How a founder can turn a whole-system idea into smaller decisions, responsibilities and review points.
After NICE: making medicines access operational
The practical steps between a medicines recommendation and a service being ready to act on it.
A trade deal is not a patient pathway
Why a trade agreement needs implementation work before it can change a patient's route to treatment.
Luxury beauty licensing: who owns the brand, formula, factory and risk?
A companion to the full founder essay, mapping the responsibilities behind a luxury beauty licence.
Read the full founder essay ↗A Luxury Beauty Licence Is a Governance System, Not a Logo Deal.
An essay about brand rights, formula ownership, manufacturing and the decisions that hold a luxury licence together.
Why formulation and analytical science should shape medicines infrastructure
Why product behaviour, measurement and process understanding belong early in plans for medicines infrastructure.
Why Glasgow City Region is being evaluated for a proposed medicines campus
The questions behind evaluating a location for a proposed medicines campus, including demand and delivery.
What makes a science campus credible?
A science campus needs a purpose, users and an operating plan. This article examines those conditions.
From medicines intelligence to campus development
Varun explains how medicines intelligence and development questions inform a longer-term campus thesis.
Designing responsible AI and robotics for future medicines operations
A defined task, human authority and a meaningful comparison provide a starting point for responsible automation.
Letter: The real test is whether invention leads to adoption
A published letter about turning invention into adoption. The original page uses an earlier byline.
Subscriber access may be required.
Why the India-UK trade deal now needs a five-gate implementation ledger
Commentary contributed by Varun to an article carrying Ross Law's publisher byline.
Five-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement Implementation
An AI-produced derivative of the Pharmaceutical Technology commentary, retained with its source relationship.
Original commentary ↗Business secures Innovate UK award for pharmaceutical manufacturing waste project
Publisher-written reporting on an Innovate UK award associated with a pharmaceutical manufacturing-waste project.
How we roll
A contribution about medicines expenditure and what different numbers describe.
NICE approval is not enough: why the UK’s next medicines challenge is operational delivery
A contributed perspective on the operational work needed after a medicines approval.
Digital Health Coffee Time Briefing
A news roundup that includes the company's funding record.
Stats US growth, Neuvior funds, Balmoral Comtec sold
A business-news roundup including the company's support announcement.
Glasgow pharmatech start-up backed by Scottish Enterprise
Reporting on Scottish Enterprise support for a defined company project.
What my dad’s corner shop taught me
The early lessons in customers, margins and trust that continue to shape Varun's approach to business.
NEUVIOR advances ZYLON programme following Innovate UK award
The research centre's account of initial feasibility work and the ZYLON programme.
Neuvior wins grant to tackle pharmaceutical sector waste with York scheme
Publisher-written reporting on a pharmaceutical-waste research project in York.
NEUVIOR Pharmaceuticals new sustainable drug trials
A local-news account of pharmaceutical manufacturing-waste research. Its original headline is retained.
Best-value biological medicines are the clearest near-term medicines productivity play in the NHS
A discussion of biological medicines, procurement and the work needed to interpret potential productivity opportunities.
NHS digital programmes do not fail on dashboards. They fail on deployment
Why the work around deployment can determine whether a digital programme becomes useful in practice.
The quarterly medicines leakage report every ICB should want in 2026/27
A proposal for examining medicines expenditure with explicit periods, denominators and local review.
The NHS has not finished the generic job
What generic-medicines data can and cannot establish about the remaining work in medicines productivity.
From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation
A finance-focused argument for evaluating a defined medicines task against its existing approach.
Why neurodivergent founders can excel at building complex systems
A perspective on neurodivergence, complex systems and the habits needed to turn an idea into work.
Why I’m building VARUNÉ Bio.
The purpose of the company and the formulation questions behind its first programmes.
The ingredient has to earn its place.
Why an unusual biological origin becomes interesting when it changes a formulation decision.
Water is not one endpoint.
The difference between taking up water, retaining it and earning a claim about skin.
Light needs a job.
Giving biochemical light a purpose that can justify the chemistry, handling and cost around it.
The kilogram after the breakthrough.
Why material development needs a defined useful output, process boundary and honest next milestone.
A source is not yet a hypothesis.
How an analytical resource can help a scientist or investor decide what evidence to seek next.
The film after the first change.
Why a formulation comparison may need to follow a material's history as well as its first result.
From retained enzyme to useful light.
The development gap between keeping an active system in a material and providing a useful signal.
The collection links to the original sources. Contribution labels distinguish bylined work, quoted views, reporting and appearances. Companion pieces and AI-produced derivatives retain their source relationships. Publisher access requirements apply.
Original dates appear where supplied. The collection was checked on 30 October 2026. Visit the press room for biographies, portraits and publication records.